Want to see AU:ALC full AI Analyst Report?
ALC Stock Chart & Stats
AU$0.10
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.10
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.08 - AU$0.15
Previous CloseN/A
Volume609.88K
Average Volume (3M)796.98K
Market Cap
AU$128.98M
Enterprise ValueAU$121.48M
Total Cash (Recent Filing)AU$14.20M
Total Debt (Recent Filing)AU$1.32M
Price to Earnings (P/E)32.8
Beta0.91
Next Earnings
Sep 02, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding1,343,558,700
10 Day Avg. Volume536,053
30 Day Avg. Volume796,979
Financial Highlights & Ratios
PEG Ratio-0.70
Price to Book (P/B)1.57
Price to Sales (P/S)3.38
P/FCF Ratio24.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.15Price Target Upside47.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)<0.01
Revenue Forecast (FY)AU$50.15M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained mid-teens revenue growth signals accelerating adoption of Alcidion's clinical software across hospitals. For a software/subscription model, durable revenue expansion improves scale economics, supports recurring contract renewals and cross-sell opportunities that can underpin multi-quarter topline momentum.
High Gross MarginVery high gross margins are characteristic of scalable software platforms and indicate efficient delivery of core products. This structural margin advantage allows the company to invest in R&D and sales while retaining potential for strong operating leverage as sales scale and fixed costs are absorbed.
Low LeverageExtremely low leverage provides financial flexibility to fund deployments, integrations and acquisitions without interest burden. A conservative balance sheet reduces solvency risk through cycles, enabling sustained investment in product development and longer sales cycles common in healthcare IT.
Bears Say
Negative EBIT MarginA negative EBIT margin indicates underlying operating losses before interest and taxes, suggesting the business still requires significant investment or has high operating costs. Over the medium term, persistent negative EBIT can limit free cash generation and impede reinvestment capacity.
Thin Net ProfitabilityA low net margin despite high gross margins implies substantial SG&A, R&D or integration costs tied to growth. If margins remain thin, the company may struggle to convert revenue into durable shareholder returns and will be sensitive to any cost inflation or contract pricing pressure.
Low Return On EquityA ROE under 2% signals limited effectiveness in converting equity into shareholder profit. This may reflect capital tied up in implementations, slow customer monetization, or early-stage scale-up costs, and suggests returns to investors could remain muted absent margin or asset efficiency gains.
Alcidion Group Limited News
ALC FAQ
What was Alcidion Group Limited’s price range in the past 12 months?
Alcidion Group Limited lowest share price was AU$0.08 and its highest was AU$0.14 in the past 12 months.
What is Alcidion Group Limited’s market cap?
Alcidion Group Limited’s market cap is AU$128.98M.
When is Alcidion Group Limited’s upcoming earnings report date?
Alcidion Group Limited’s upcoming earnings report date is Sep 02, 2026 which is in 64 days.
How were Alcidion Group Limited’s earnings last quarter?
Alcidion Group Limited released its earnings results on Feb 25, 2026. The company reported AU$0.001 earnings per share for the quarter, beating the consensus estimate of AU$0 by AU$0.001.
Is Alcidion Group Limited overvalued?
According to Wall Street analysts Alcidion Group Limited’s price is currently Undervalued.
Does Alcidion Group Limited pay dividends?
Alcidion Group Limited does not currently pay dividends.
What is Alcidion Group Limited’s EPS estimate?
Alcidion Group Limited’s EPS estimate is 0.
How many shares outstanding does Alcidion Group Limited have?
Alcidion Group Limited has 1,343,558,700 shares outstanding.
What happened to Alcidion Group Limited’s price movement after its last earnings report?
Alcidion Group Limited reported an EPS of AU$0.001 in its last earnings report, beating expectations of AU$0. Following the earnings report the stock price went down -4.545%.
Which hedge fund is a major shareholder of Alcidion Group Limited?
Currently, no hedge funds are holding shares in AU:ALC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alcidion Group Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$0.15 (47.50% Upside)
AU$0.15 (47.50% Upside)
Blogger Sentiment
Bullish
AU:ALC Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
66.66%
12-Months-Change
Fundamentals
Return on Equity
4.37%
Trailing 12-Months
Asset Growth
3.82%
Trailing 12-Months
Company Description
Alcidion Group Limited
Alcidion Group Limited operates as a healthcare technology firm, specializing in the creation and licensing of software products across Australia, New Zealand, and the United Kingdom. Its flagship product, Miya Precision, is a consolidated platform built on the Fast Healthcare Interoperability Resources (FHIR) standard, aimed at enabling intelligent healthcare delivery. The company also supplies Smartpage, a mobile and web-based system designed to streamline hospital communications and task management for clinical and administrative personnel. Additional solutions include Patientrack, a tool for real-time patient monitoring and risk screening; Silverlink, which handles patient administration; and ExtraMed, software dedicated to optimizing clinical and patient flow. Furthermore, Alcidion provides a range of services encompassing product deployment, support and maintenance, systems integration, and data analysis. Founded in 2000 and headquartered in South Yarra, Australia, the company was formerly known as Alcidion Corporation Pty Ltd until its rebranding as Alcidion Group Limited in December 2015.
ALC Stock 12 Month Forecast
Average Price Target
AU$0.15
▲(47.50% Upside)
Technical Analysis
Oneview Healthcare Chess Depository Interests repr 1
―
Mach7 Technologies
―
Beamtree Holdings Ltd
―
Singular Health Group Ltd
―
PainChek Ltd
―
Options Prices
Currently, No data available
---








